217 related articles for article (PubMed ID: 12912932)
1. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
2. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Dudkin L; Dilling MB; Cheshire PJ; Harwood FC; Hollingshead M; Arbuck SG; Travis R; Sausville EA; Houghton PJ
Clin Cancer Res; 2001 Jun; 7(6):1758-64. PubMed ID: 11410517
[TBL] [Abstract][Full Text] [Related]
3. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
Tirado OM; Mateo-Lozano S; Notario V
Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
[TBL] [Abstract][Full Text] [Related]
7. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
Shor B; Zhang WG; Toral-Barza L; Lucas J; Abraham RT; Gibbons JJ; Yu K
Cancer Res; 2008 Apr; 68(8):2934-43. PubMed ID: 18413763
[TBL] [Abstract][Full Text] [Related]
8. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
[TBL] [Abstract][Full Text] [Related]
10. Arginine and Leucine regulate p70 S6 kinase and 4E-BP1 in intestinal epithelial cells.
Ban H; Shigemitsu K; Yamatsuji T; Haisa M; Nakajo T; Takaoka M; Nobuhisa T; Gunduz M; Tanaka N; Naomoto Y
Int J Mol Med; 2004 Apr; 13(4):537-43. PubMed ID: 15010853
[TBL] [Abstract][Full Text] [Related]
11. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
12. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Atkins MB; Hidalgo M; Stadler WM; Logan TF; Dutcher JP; Hudes GR; Park Y; Liou SH; Marshall B; Boni JP; Dukart G; Sherman ML
J Clin Oncol; 2004 Mar; 22(5):909-18. PubMed ID: 14990647
[TBL] [Abstract][Full Text] [Related]
15. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Hosoi H; Dilling MB; Shikata T; Liu LN; Shu L; Ashmun RA; Germain GS; Abraham RT; Houghton PJ
Cancer Res; 1999 Feb; 59(4):886-94. PubMed ID: 10029080
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
Burczynski ME; Twine NC; Dukart G; Marshall B; Hidalgo M; Stadler WM; Logan T; Dutcher J; Hudes G; Trepicchio WL; Strahs A; Immermann F; Slonim DK; Dorner AJ
Clin Cancer Res; 2005 Feb; 11(3):1181-9. PubMed ID: 15709187
[TBL] [Abstract][Full Text] [Related]
18. Phospholipase D confers rapamycin resistance in human breast cancer cells.
Chen Y; Zheng Y; Foster DA
Oncogene; 2003 Jun; 22(25):3937-42. PubMed ID: 12813467
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
Raymond E; Alexandre J; Faivre S; Vera K; Materman E; Boni J; Leister C; Korth-Bradley J; Hanauske A; Armand JP
J Clin Oncol; 2004 Jun; 22(12):2336-47. PubMed ID: 15136596
[TBL] [Abstract][Full Text] [Related]
20. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates.
Dekter HE; Romijn FP; Temmink WP; van Pelt J; de Fijter JW; Smit NP
Anal Biochem; 2010 Aug; 403(1-2):79-87. PubMed ID: 20417611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
